ARTICLE | Clinical News

CP-4126: Phase I data

September 22, 2008 7:00 AM UTC

In a dose-finding Phase I trial in 32 patients with solid tumors, the MTD of CP-4126 was 1,600 mg/m 2/day when administered as a 30-minute infusion on days 1, 8 and 15 in a 4-week schedule. Dose-limit...